Between this list of twelve, critical clinical developments have been made with Melanoma-Associated Antigen 3 (MAGE-A3) and New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) antigen vaccines. Here, MAGEA3 is linked to esophagitis.